^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    IL12RB1 (Interleukin 12 Receptor Subunit Beta 1)

    i
    Other names: IL12RB1, Interleukin 12 Receptor Subunit Beta 1, Interleukin-12 Receptor Subunit Beta-1, Interleukin 12 Receptor, Beta 1, IL-12 Receptor Beta Component, IL-12 Receptor Subunit Beta-1, IL-12R Subunit Beta-1, IL12RB, CD212, Interleukin-12 Receptor Beta-1 Chain, Cluster Of Differentiation 212, IL-12R-Beta-1, CD212 Antigen, IL-12R-BETA1, IMD30, IL12R
    2ms
    Decoding epigenetic and transcriptional landscapes: DNA methylome-transcriptome integration reveals novel drivers in 4NQO-Induced esophageal squamous cell carcinoma mouse model. (PubMed, Clin Epigenetics)
    These findings highlight ESSH as a critical window where epigenetically driven immune changes facilitate ESCC progression. Targeting these early epigenetic-immune interactions may offer a novel strategy for ESCC early detection and combination therapy.
    Preclinical • Journal
    |
    PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • IL12RB1 (Interleukin 12 Receptor Subunit Beta 1)
    3ms
    GBP1 as a machine learning-prioritized biomarker and therapeutic target for epstein-barr virus-induced clear cell renal cell carcinoma: multi-omics causal validation. (PubMed, Int J Surg)
    This work reveals a causal relationship between EBV infection and ccRCC pathogenesis, establishing GBP1 as a top-priority candidate molecule through a multi-level, multi-dimensional evidence framework. Drug prediction and molecular docking suggest finasteride as a potential inhibitor of GBP1, offering new strategies for the precise prevention and treatment of ccRCC.
    Journal
    |
    GBP5 (Guanylate Binding Protein 5) • GBP1 (Guanylate Binding Protein 1) • IFI16 (Interferon Gamma Inducible Protein 16) • IL12RB1 (Interleukin 12 Receptor Subunit Beta 1) • RECQL (RecQ Like Helicase)
    |
    finasteride
    3ms
    Bone marrow-based highly sensitive proteomics profiling reveals valuable biomarkers for pediatric B-cell acute lymphoblastic leukemia. (PubMed, Cancer Lett)
    In addition, we found that higher levels of DEPs, such as CD27, TNF, CCL3, CCL4, IL12RB1, PDCD1, and GZMB, in patients with genetic alterations associated with poor prognosis. Our Olink proteomics analysis identified nine key proteins that were differentially expressed between the pediatric B-ALL and control groups, which may contribute to the diagnosis and/or risk stratification of pediatric B-ALL.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • IL6 (Interleukin 6) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CD27 (CD27 Molecule) • GZMB (Granzyme B) • CCL3 (C-C Motif Chemokine Ligand 3) • IL12RB1 (Interleukin 12 Receptor Subunit Beta 1) • ADGRG1 (Adhesion G Protein-Coupled Receptor G1) • NCR1 (Natural Cytotoxicity Triggering Receptor 1)
    6ms
    CRISPRi Screening Identifies SON and MAP4K1 as Regulators of Type III Cytokine Expression in Innate Lymphoid Cells. (PubMed, bioRxiv)
    Depletion of MAP4K1 in MNK3 also enhanced expression of the type I cytokine, IFNg, which was co-expressed with IL-17, a phenotype reminiscent of pathogenic Th17 cells. Together, results from the CRISPRi screen broaden our understanding of the factors involved in type III immune responses and offer new targets for modulating IL-22/17 expression.
    Journal
    |
    IFNG (Interferon, gamma) • IL17A (Interleukin 17A) • IL23A (Interleukin 23 Subunit Alpha) • IL12RB1 (Interleukin 12 Receptor Subunit Beta 1) • IL1B (Interleukin 1, beta) • IL22 (Interleukin 22)
    6ms
    Soluble Oncoimmunome Signatures Predict Muscle Mass Response to Enriched Immunonutrition in Cancer Patients: Subanalysis of a Multicenter Randomized Clinical Trial. (PubMed, Nutrients)
    Our findings support the use of enriched oral nutritional supplementation (ONS) as an effective strategy not only to enhance caloric and protein intake but also to promote anabolism and preserve muscle mass in cancer patients. The identification of immune profiles suggests that specific biomarkers could be used to predict which patients will benefit most from this type of intervention. This may allow for the implementation of personalized immunonutrition strategies that optimize resource allocation and improve clinical outcomes, particularly in vulnerable populations at risk of cachexia.
    Clinical • Journal • IO biomarker
    |
    LAMP3 (Lysosomal Associated Membrane Protein 3) • IL12RB1 (Interleukin 12 Receptor Subunit Beta 1)
    over1year
    Analysis of Methylome of Different Forms of Basal Cell Hyperplasia and Squamous Cell Metaplasia of Bronchial Epithelium. (PubMed, Bull Exp Biol Med)
    Differentially methylated regions affecting genes involved in inflammation regulation (IL-23, IL-23R, IL12B, IL12RB1, and FIS1) were detected in SM combined with dysplasia in comparison with SM combined with BCH. The revealed changes in DNA methylation may underlie various "scenarios" of the precancerous process in the bronchial epithelium.
    Journal
    |
    IL23A (Interleukin 23 Subunit Alpha) • IL12RB1 (Interleukin 12 Receptor Subunit Beta 1)
    over1year
    A predictive study of genes related to lactic acid metabolism in cervical carcinoma. (PubMed, J Obstet Gynaecol Res)
    Lactic acid metabolism is closely related to the prognosis of cervical carcinoma, where the immune microenvironment may play an important role.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • ENO1 (Enolase 1) • IL12RB1 (Interleukin 12 Receptor Subunit Beta 1) • EGLN1 (Egl-9 Family Hypoxia Inducible Factor 1)
    over2years
    Overcoming lung cancer immunotherapy resistance by combining non-toxic variants of IL-12 and IL-2. (PubMed, JCI Insight)
    Administering IL-12 and IL-2 analogs with preferential binding to cells expressing IL12rb1 and CD25, respectively, led to a significant extension of survival in mice with lung tumors while abrogating dose-limiting toxicity. These findings suggest that IL-12 and IL-2 represent a rational approach to combination cytokine therapy whose dose-limiting toxicity can be overcome with engineered cytokine variants.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • IL12RB1 (Interleukin 12 Receptor Subunit Beta 1) • ISG20 (Interferon Stimulated Exonuclease Gene 20)
    over2years
    Murine cytotoxic CD4+ T cells in the tumor microenvironment are at a hyper-maturation stage of Th1 CD4+ T cells sustained by IL-12. (PubMed, Int Immunol)
    Finally, we used pathway analysis and ex vivo stimulation to confirm that the Foxp3-CD4+ T cells expressed higher levels of IL12rb1 genes and were activated by the IL-12/IL-27 pathway. In conclusion, this work finds that, in late-stage tumors, the tumor-infiltrating lymphocyte population of CD4+ cells harbored a sustained, hyper-maturated Th1 status with cytotoxic function supported by IL-12.
    Preclinical • Journal
    |
    CD4 (CD4 Molecule) • GZMB (Granzyme B) • FOXP3 (Forkhead Box P3) • IL12RB1 (Interleukin 12 Receptor Subunit Beta 1) • PRF1 (Perforin 1)
    |
    FOXP3 expression
    over2years
    A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma. (PubMed, Cell Rep Med)
    We develop a bispecific T cell engager targeting ILT3 that shows potent killing effects in vitro and decreased tumor burden and prolonged mice survival in vivo, suggesting therapeutic relevance. Our study uncovers MM-associated antigens that hold great promise for immune-based therapies of MM.
    Journal • IO biomarker
    |
    IL12RB1 (Interleukin 12 Receptor Subunit Beta 1) • LRRC8D (Leucine Rich Repeat Containing 8 VRAC Subunit D)
    over2years
    Lymphoproliferation- a clue towards an underlying monogenic disorder of immune dysregulation- a retrospective analysis from a single center in India (CIS 2023)
    Treatment included IVIG, chemotherapy, rituximab, sirolimus, abatacept, HSCT. Lymphomas presenting at abnormal site and/or age, relapse and EBV driven lymphomas require further evaluation. Presence of monogenic cause helps in providing targeted therapy.
    Retrospective data • IO biomarker
    |
    TET2 (Tet Methylcytosine Dioxygenase 2) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4) • IL2RA (Interleukin 2 receptor, alpha) • PIK3R1 (Phosphoinositide-3-Kinase Regulatory Subunit 1) • CARD11 (Caspase Recruitment Domain Family Member 11) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta) • FASLG (Fas ligand) • TNFAIP3 (TNF Alpha Induced Protein 3) • CASP8 (Caspase 8) • BACH2 (BTB Domain And CNC Homolog 2) • IL12RB1 (Interleukin 12 Receptor Subunit Beta 1) • TCL1A (TCL1 Family AKT Coactivator A) • IKBKB (Inhibitor Of Nuclear Factor Kappa B Kinase Subunit Beta)
    |
    Rituxan (rituximab) • sirolimus